@article{abcb5221e9f8403099b71e77ebf37e57,
title = "Going for the gold: A description of the centers of excellence designation by the Infectious Diseases Society of America",
abstract = "Antimicrobial stewardship programs (ASPs) are recommended by the Centers for Disease Control and Prevention and World Health Organization and mandated by the Joint Commission to curb antimicrobial resistance. However, <50% of institutions have optimal ASPs in place. Building on its experience of antimicrobial stewardship (AMS) advocacy, the Infectious Diseases Society of America (IDSA) developed the AMS Centers of Excellence (CoE) program, which will serve as a conduit to share best practices and highlight the standards for other hospitals to achieve in order to advance the field of AMS. A designation of CoE signifies that these institutions deliver high-quality care consistently, serve as the “gold” standard for executing novel AMS principles, and demonstrate commitment to their ASP. Here, we describe the process and purpose of designating institutions as AMS CoEs, provide awareness to clinicians on opportunities available through IDSA with this CoE designation, and discuss the evolution of the program.",
keywords = "Antibiotic resistance, Antimicrobial stewardship, Centers of excellence, Infectious Diseases Society of America, Infectious diseases",
author = "Ravina Kullar and Jerod Nagel and Bleasdale, {Susan C.} and Sutton, {Sarah H.} and Snezana Naumovski and Andres Rodriguez and Cheryl Smith and James Leggett and Goldstein, {Ellie J.C.}",
note = "Funding Information: Potential conflicts of interest. S. C. B. has served on advisory boards for the Medicines Company and has received research grants from Rempex Pharmaceuticals, Inc., and Shionogi, USA Inc. E. J. C. G. has served on advisory boards for Merck & Co., Bayer Pharmaceuticals, BioK+, Cutis Pharmaceuticals, Sanofi-Adventis, Summit Corp. plc, Kindred Healthcare Corp., Sankyo-Daichi, Paratek Pharma, and Shionogi Inc.; has been on speakers{\textquoteright} bureau for Bayer Inc., Merck & Co., Medicines Co., and Allergan Inc.; and has received research grants from Bayer Inc., Cutis Pharmaceuticals, Entasis Therapeutics, Merck & Co., Micromyx LLC, Parateck Pharmaceuticals, Spero Therapeutics, and Tetraphase Therapeutics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.",
year = "2019",
month = may,
day = "1",
doi = "10.1093/cid/ciy797",
language = "English (US)",
volume = "68",
pages = "1777--1782",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",
}
